No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VTYX240517P5000
- 1.10
- +0.35+46.67%
15min DelayClose May 10 15:59 ET
1.10High1.10Low
1.10Open0.75Pre Close3 Volume81 Open Interest5.00Strike Price330.00Turnover142.73%IV-1.59%PremiumMay 17, 2024Expiry Date0.91Intrinsic Value100Multiplier6DDays to Expiry0.19Time Value100Contract SizeAmericanOptions Type-0.8245Delta0.3268Gamma4.19Leverage Ratio-0.0145Theta-0.0007Rho-3.46Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Ventyx Biosciences: A Prudent Hold Amidst Promising Drug Potential and Market Uncertainties
Buy Rating for Ventyx Biosciences Based on Clinical and Financial Strengths
Express News | Ventyx Biosciences Inc - Qtrly Net Loss $38.6 Mln
Ventyx Biosciences | 10-Q: Quarterly report
Comments
$Ventyx Biosciences(VTYX.US$ $NIO Inc(NIO.US$ $Eli Lilly and Co(LLY.US$ $Structure Therapeutics(GPCR.US$
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Morning Movers
Gapping up
$Oracle(ORCL.US$ The information technology company saw its stock climb 13.3% due to strong per-share earnings, with adjusted earnings per share of $1.41 surpassing the consensus estimate.
$Kohl's Corp(KSS.US$ The retailer's shares increased by 2.2% after reporting earnings and revenue that exceeded expectations for the fourth quarter.
$Coinbase(COIN.US$ The cryptocurrency trading platform's shares...
Gapping up
$Oracle(ORCL.US$ The information technology company saw its stock climb 13.3% due to strong per-share earnings, with adjusted earnings per share of $1.41 surpassing the consensus estimate.
$Kohl's Corp(KSS.US$ The retailer's shares increased by 2.2% after reporting earnings and revenue that exceeded expectations for the fourth quarter.
$Coinbase(COIN.US$ The cryptocurrency trading platform's shares...
23
3
$Ventyx Biosciences (VTYX.US)$ good breakout and gapfill zone at 13.5. Fda approvals in pipeline. Good to play upside momentum with stoploss 6
1
The stock market started off on a good note and really picked up speed at 10 pm (GST +8) after a very positive ISM Manufacturing report, which showed just the right balance of growth without too much inflation. On top of that, the tech sector, which was already doing well, received an extra boost from a highly praised report by DELL. By the end of the trading session, stocks closed near their highest points for the day, with more stocks reaching new highs on both maj...
15
Read more